Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 149 Publications

25 Customer Reviews

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NVLYWmJYS3m2b4TvfIlkKEG|c3H5 NYDaOpRyPTBizszN NFe4bZA1QCCq M2DZSGROW09? NX3s[pRGU2mubIOgZ4VtdHNiYomgcY9z\SC2aHHuJFk6LQ>? MUSxNFQ6QTZ2Mx?=
OVCA 429 MkHJSpVv[3Srb36gRZN{[Xl? MX[zNFAhdk1? NVvsemVOPDhiaB?= NGTke4NFVVOR NWTxWGNYTGm|coXweJMhcW62YXP0JI12dHSrY3XscJVt[XJidIXtc5Ihe3CqZYLvbYR{ M3jOWFExQTl7N{[2
RPMI8226 M1nxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7xNVAxKG6P M1z0[|Q5KGh? M{HRTmROW09? M2TLcmlEPTB;M{Cgcm0> MlPSNVE{ODZ2OEm=
Dox40 NWP1UpdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\uTllEOTByIH7N MkHUOFghcA>? MVvEUXNQ NHjvZldKSzVyPUSwJI5O NYLZS3E2OTF|ME[0PFk>
MR20 NVjERllJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1qwNFExOCCwTR?= MXq0PEBp MkWxSG1UVw>? M4OzdGlEPTB;MkCgcm0> M120[lEyOzB4NEi5
LR5 Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1KyZVExOCCwTR?= Mki4OFghcA>? NYDEcopKTE2VTx?= NXXr[Y9DUUN3ME2yNEBvVQ>? MUixNVMxPjR6OR?=
U266 M2TuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPUNYIyODBibl2= MYi0PEBp M1;semROW09? MW\JR|UxRTNibl2= NXyw[XpxOTF|ME[0PFk>
IM-9 M2X4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrsSYQyODBibl2= MkLaOFghcA>? NVLEWm9NTE2VTx?= M1XQZWlEPTB;NjDuUS=> MlrrNVE{ODZ2OEm=
Hs Sultan M4jXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzENVAxKG6P M3zORVQ5KGh? MVjEUXNQ MnToTWM2OD1{MDDuUS=> MVWxNVMxPjR6OR?=
PAM-LY2 NFLGdXpHfW6ldHnvckBCe3OjeR?= MknRNVAxKG6P NV\0OYt1OTJiaB?= NGXwZmdFVVOR NYPNcnh1UW6qaXLpeJMhVkZvzsrCJIFkfGm4YYTpc44> NIjqSpAyOTN3MEmxNy=>
PAM 212 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6xNFAhdk1? M3f1[lczKGh? MWrEUXNQ MnrsTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NWnhTZpyOTF|NUC5NVM>
PAM-LY2 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCxNFAhdk1? MnfCO|IhcA>? NIrxU4xFVVOR NGnxV|NKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MWmxNVM2ODlzMx?=
B4B8 M{LvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGxNFAhdk1? MlnDO|IhcA>? MnPSSG1UVw>? M1HJXGlvcGmkaYTzJINmdGxidnnhZoltcXS7 NEDybooyOTN3MEmxNy=>
B7E3 NVvpZWROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGxNFAhdk1? M2iyXVczKGh? NIrnN5NFVVOR MmD6TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MXSxNVM2ODlzMx?=
UM-SCC-9 NUDVOolLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjGd2RXOTByIH7N MkfqO|IhcA>? MV7EUXNQ NGLXfZJKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MmjDNVE{PTB7MUO=
UM-SCC-11B NEHhfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK1NVAxKG6P MlnTO|IhcA>? M1\wU2ROW09? NGOzfFFKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NVXnWY5MOTF|NUC5NVM>
H460 NFTNR2ZHfW6ldHnvckBCe3OjeR?= NEjjVm0yOCEQvF2= NFvQPZkzPCCq NE\NPFFFVVOR MYjJcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 NVWwTGtQOTJ2OUKxNVc>
U266 M1HqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHB[Fk3PTByIH7nM41t NH7sOI01QCCq NFvIXndFVVOR MkPQTY5pcWKrdIOgZ4VtdCCpcn;3eIg> Mn7MNVI3OzF4MUm=
ARH77 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q3eVUxOCCwZz;tcC=> M3PKUlQ5KGh? MlHkSG1UVw>? Ml[5TY5pcWKrdIOgZ4VtdCCpcn;3eIg> NEPBVZYyOjZ|MU[xPS=>
WAD-1 NIPVRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG1NFAhdmdxbXy= NVzqNWZlPDhiaB?= M2m3eWROW09? M13pcWlvcGmkaYTzJINmdGxiZ4Lve5Rp MoO3NVI3OzF4MUm=
U266/LR7 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:1NFAhdmdxbXy= MkfyOFghcA>? NEG1W25FVVOR Mnq5TY5pcWKrdIOgZ4VtdCCpcn;3eIg> MnHTNVI3OzF4MUm=
U266/dox4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLqOVAxKG6pL33s MVe0PEBp NWT4cmh5TE2VTx?= NGnQZmtKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NYnYWlRLOTJ4M{G2NVk>
RPMI8226/LR5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrpOVAxKG6pL33s M3W2cVQ5KGh? NYXHbIVbTE2VTx?= NUn2d4lwUW6qaXLpeJMh[2WubDDndo94fGh? MXOxNlY{OTZzOR?=
H460 NWTBWppuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLSO|IyOCEQvF2= NEXn[GU4OiCq MVrEUXNQ M4PVVGlEPTB;MUCwJI5O MVKxNlY{OTZ{MB?=
H358 MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zUSVExKM7:TR?= MUK3NkBp M3XoU2ROW09? NHHhPIZKSzVyPUewJI5O M2fvWFEzPjNzNkKw
H322 NF\WWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqxNEDPxE1? NEDHVlM4OiCq M13ue2ROW09? NF31fIpKSzVyPU[yNEBvVQ>? M4LXfFEzPjNzNkKw
H460 MXXGeY5kfGmxbjDBd5NigQ>? NUO4VJVSOTByIH7N NHLBUGszPCCq MYHEUXNQ MkW5TY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>? M1fEPVEzPjNzNkKw
LNCap-Pro5 M2HHc2Z2dmO2aX;uJGF{e2G7 NEjSOZIyKM7:TR?= MoTrOEBp M4LGeWROW09? MkHwV5Ri[mmuaYrld{BxPTN? NW[5ZohLOTR4MUK1N|I>
T29 NYjFbHh6SXCxcITvd4l{KEG|c3H5 M3nsS|UxKG6P Ml60OFghcCB? NFzodHhFVVOR NXfwOIwyUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MkTRNVY4PzhzN{m=
T29Kt1 Mlr5RZBweHSxc3nzJGF{e2G7 NUDHOm8yPTBibl2= M{[1TFQ5KGhi MV;EUXNQ NVjCXolsUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MUOxOlc4QDF5OR?=
HCT116 Mlz6RZBweHSxc3nzJGF{e2G7 M{PJO|UxKG6P M4HZdFQ5KGhi Mk\SSG1UVw>? MnnVTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M1zRflE3Pzd6MUe5
HKe-3 NWTRWmh[SXCxcITvd4l{KEG|c3H5 MVS1NEBvVQ>? NYjLe|g5PDhiaDC= NUPEZmFTTE2VTx?= M2PMc2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MVixOlc4QDF5OR?=
NB-1691 NYC2TZdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TjSVEh|ryP MkjtO|IhcA>? NEWxOnpKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW= M3nZNFE4Pjh7Nki0
CHLA-255 NUC0S|Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6xJO69VQ>? NUnHfXFtPzJiaB?= NHXRc49KdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMjW= NWjmPWdyOTd4OEm2PFQ>
SK-N-AS M1;GWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q0fFEh|ryP NXPpXG9IPzJiaB?= NIH4TnJKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMUCl NYToRYU2OTd4OEm2PFQ>
NB-1691 NEW4dJZHfW6ldHnvckBCe3OjeR?= NWfLXZVjOTBibl2= Mlm0NlQhcA>? NWq3[oc4W2mpbnnmbYNidnSueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? NWLzNlZtOTd4OEm2PFQ>
CHLA-255 M{n1PWZ2dmO2aX;uJGF{e2G7 NXvnSGYyOTBibl2= NYD4O|d2OjRiaB?= MUDNc4Rme3SueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? NWTU[YJiOTd4OEm2PFQ>
RPMI 8226 NWDVT4NyTnWwY4Tpc44hSXO|YYm= NUfUc5dsOjBibl2= NGrs[pU5KGh? NEfoXW9UcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NFHGVW8yQTR|NkC1NC=>
MM.1S NESxOVZHfW6ldHnvckBCe3OjeR?= NHr4VXIzOCCwTR?= NH\FSI85KGh? NVvMZm9FW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NG\uOoEyQTR|NkC1NC=>
U266 NVXXVodwTnWwY4Tpc44hSXO|YYm= M3TlPVIxKG6P NIPDU2g5KGh? NEDhO3dUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NXz2SIFSOTl2M{[wOVA>
OPM1 MlnMSpVv[3Srb36gRZN{[Xl? M3u4cVIxKG6P M2jiT|ghcA>? M2nFVXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MoTENVk1OzZyNUC=
INA6 NYXucYFwTnWwY4Tpc44hSXO|YYm= NX7RVHZsOjBibl2= NX7s[2NMQCCq Ml3GV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MorVNVk1OzZyNUC=
OPM2 MUfGeY5kfGmxbjDBd5NigQ>? MVeyNEBvVQ>? M{\XNFghcA>? Mmn3V4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> NYLZW|NYOTl2M{[wOVA>
RPMI 8226 MnvCSpVv[3Srb36gRZN{[Xl? NHWwcoQzOCCwTR?= MXe4JIg> MXzJcoR2[2W|IFTORUB{gW62aHXzbZM> NWfJS5ZrOTl2M{[wOVA>
BaF/3 MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe5c|AyODBibl2= MkniOFghcA>? MYDJR|UxRTZwMjDuUS=> NFHOfpYzODNyNU[5Ni=>
BaF/3-p210 M{DMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfyNVAxKG6P NEHtZ5M1QCCq MWLJR|UxRTRwNzDuUS=> NVP6Z2I6OjB|MEW2PVI>
TCC-S M3r1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6xNFAhdk1? NG[xOYM1QCCq NYnFNZh6UUN3ME2yMlghdk1? NUT5ZmRVOjB|MEW2PVI>
BaF/3 M4PL[2Z2dmO2aX;uJGF{e2G7 M3fSelYhdk1? Moj3OFghcA>? MljYTY5lfWOnczDhJIdz\WG2IFexJINmdGxvY4njcIUh[XK{ZYP0 NYDRblRPOjB|MEW2PVI>
BaF/3-p210 MVzGeY5kfGmxbjDBd5NigQ>? M4facFYhdk1? M2XWSFQ5KGh? MYLJcoR2[2W|IHGgd4xq\2i2IFexJINmdGxvY4njcIUh[XK{ZYP0 MoTxNlA{ODV4OUK=
BaF/3-p210 M4K5fWZ2dmO2aX;uJGF{e2G7 MYe2JI5O NWjTV|RuOjRiaB?= MVXS[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gZY5lKHSqZTDhZ5Rqfmm2eTDv[kBT[g>? MYeyNFMxPTZ7Mh?=
Raji MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLyNUDPxE1? M1vBUlI1KGh? NV73eHNSWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NYW4WlI{OjFzN{C5PFg>
LCL-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX61SHhUOSEQvF2= NYnNeIYzOjRiaB?= MWnS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MWKyNVE4ODl6OB?=
LCL-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T6W|Eh|ryP NHjY[XYzPCCq NXHmUFJ[WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NHnXbFEzOTF5MEm4PC=>
BJAB M1HoPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSxJO69VQ>? M3T0VFI1KGh? Mnq2VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NH7EdIszOTF5MEm4PC=>
SNT-13 NITBcJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r4ZlEh|ryP NYDmU2s1OjRiaB?= NEm3NmNT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NVeyOpQ{OjFzN{C5PFg>
SNT-16 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3Tbol2OSEQvF2= MkfKNlQhcA>? NVKyeJBqWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MVyyNVE4ODl6OB?=
Jurkat MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGxJO69VQ>? Mk[4NlQhcA>? NWTEeW46WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NXK3W2g5OjFzN{C5PFg>
KAI-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HDWVEh|ryP NYTCeZhmOjRiaB?= MYrS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NGfiT3AzOTF5MEm4PC=>
SNK-6 MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWxJO69VQ>? NH3hfXgzPCCq MUPS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NF74OpczOTF5MEm4PC=>
KHYG-1 MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jPdFEh|ryP MWiyOEBp NEPnOWRT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MlnlNlEyPzB7OEi=
SNT-16 NXTCXXBlSXCxcITvd4l{KEG|c3H5 M4jwbFEh|ryP MYi2JIg> M17FOWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M2TJblIyOTdyOUi4
Jurkat MXnBdI9xfG:|aYOgRZN{[Xl? NYDrVWNSOSEQvF2= MoTlOkBp M13wNWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NEf0NVAzOTF5MEm4PC=>
KAI-3 NHL6XGFCeG:ydH;zbZMhSXO|YYm= NUDBU2VqOSEQvF2= NX7nNYYyPiCq MWLJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFLR[XQzOTF5MEm4PC=>
KHYG-1 NHPUdI1CeG:ydH;zbZMhSXO|YYm= NYTXZ2JMOSEQvF2= NFX6Ono3KGh? MWDJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MoPGNlEyPzB7OEi=
SNT-13 NFLmN3BCdnSrdnnyZYwhSXO|YYm= M4HYcFEh|ryP Mmn1NlQhcA>? NGP1XpRKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MUWyNVE4ODl6OB?=
SNT-16 MorZRY51cX[rcnHsJGF{e2G7 NXj3OXpoOSEQvF2= Mm\ENlQhcA>? MmPXTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NHTEbYUzOTF5MEm4PC=>
KAI-3 M2nzWmFvfGm4aYLhcEBCe3OjeR?= MXexJO69VQ>? NWPISo9COjRiaB?= NXrvVJk3UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MXuyNVE4ODl6OB?=
SNK-6 M3rjN2FvfGm4aYLhcEBCe3OjeR?= MojqNUDPxE1? MlXzNlQhcA>? Mo[xTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX MlT0NlEyPzB7OEi=
RAW 264.7 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jEflExOCCwTR?= MV:0PEBp Ml3QVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MVGyNlQzPzF3NB?=
A375 MlzmRZBweHSxc3nzJGF{e2G7 MUKxNEBvVQ>? NEjCUnAzPCCq NFj6fGRKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NV76e5VQOjNyN{mwPFM>
BLM NFe0R3BCeG:ydH;zbZMhSXO|YYm= MVGxNEBvVQ>? MX:yOEBp M3zKXGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NYHiVWRUOjNyN{mwPFM>
A375 M{HsUGF2fG:yaHHnfUBCe3OjeR?= MXexNEBvVQ>? M1HZUVEzKGh? NVz3UodrUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> MVmyN|A4QTB6Mx?=
BLM NHXUSlJCfXSxcHjh[5khSXO|YYm= NUfHW49rOTBibl2= M{PZd|EzKGh? NYG1WXM5UW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> M3u4RVI{ODd7MEiz
H1299 NXe3blJvSXCxcITvd4l{KEG|c3H5 MUO4NEBvVQ>? MkDNNlQhcA>? NW\YUYxpTE2VTx?= M3PVTXNmdnOrdHn6[ZMhVlOFTFOgZ4VtdHNidH:gUXNENWSncnn2[YQhcUN7LXnu[JVk\WRiYYDvdJRwe2m| NXf1d3JnOjV|MkO2PVM>
Hut-78 M3Tz[2Z2dmO2aX;uJGF{e2G7 MXOxNFAhdk1? NXLIOo1tOjRiaB?= NHSxT4dFVVOR M2PWTWRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?= NFrONHIzPTZ6MUOzOS=>
H9 MnTJSpVv[3Srb36gRZN{[Xl? MYSxNFAhdk1? NWD5boIzOjRiaB?= MVLEUXNQ Mn3TSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOSCneIDy[ZN{cW:w NV\uVmJGOjV4OEGzN|U>
HH M3LIW2Z2dmO2aX;uJGF{e2G7 NHTsV|UyODBibl2= NGjmdHkzPCCq M3;nbGROW09? NV7Vdo1H\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u M13pOVI2PjhzM{O1
Hut-78 MULNbYdz[XSrb36gRZN{[Xl? NYLVTJNYOTByIH7N NIi5N4czPCCq M1nIcGROW09? MX\S[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBn MXqyOVY5OTN|NR?=
HH Mlf6UYloemG2aX;uJGF{e2G7 NHXEV|cyODBibl2= M{L4elI1KGh? MWHEUXNQ NHnZUHpT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUGl NUfhO3NxOjV4OEGzN|U>
U937 M3nQ[WZ2dmO2aX;uJGF{e2G7 Mk\sNVAxKG6P M4jyXFYhcA>? MV3JcoR2[2W|IFnMMVgh\XiycnXzd4lwdiCrbjDMVHMue3SrbYXsZZRm\CCXOUO3JI1i[3KxcHjh[4V{ NH\wPVEzPTd7MUS3Oy=>
human PBMC NInoZ|RHfW6ldHnvckBCe3OjeR?= MoPnNVAxKG6P NYq3VpZROjRiaB?= Ml7HTY5lfWOnczDJUE05KHKnbHXhd4U> NILObI4zPTd7MUS3Oy=>
ES6 NVHlV3R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPKTWM2OD1yLkCwNlEhdk1? MkjBV2FPT0WU
SK-UT-1 NYfGfZF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXTcJdKSzVyPUCuNVY{KG6P NILrSIdUSU6JRWK=
SH-4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\DNmlEPTB;MD6xO|Mhdk1? NGOyPHBUSU6JRWK=
TE-9 NGXXfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu1TWM2OD1yLkG4NkBvVQ>? NF7E[JNUSU6JRWK=
A253 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMkC4JI5O NIfHPHBUSU6JRWK=
no-10 M{f5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMkGgcm0> NHP4eZFUSU6JRWK=
MMAC-SF NXv0XYZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjEW|Z7UUN3ME2wMlIyPiCwTR?= M1vqfnNCVkeHUh?=
A101D NXT3OFVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjBTWM2OD1yLkKyOUBvVQ>? NVjCXnlvW0GQR1XS
NTERA-S-cl-D1 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXOUWNtUUN3ME2wMlI1OyCwTR?= NVz3WoJ4W0GQR1XS
8-MG-BA MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFi3cphKSzVyPUCuNlUhdk1? M4La[HNCVkeHUh?=
KNS-42 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIGzcFFKSzVyPUCuNlU5KG6P MYXTRW5ITVJ?
LXF-289 M161[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\FTWM2OD1yLkK2PUBvVQ>? M3HNUnNCVkeHUh?=
OVCAR-4 M2\weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjUUFZKSzVyPUCuNlg6KG6P MmrtV2FPT0WU
LOUCY MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7EOpRKSzVyPUCuNlk{KG6P M3Xud3NCVkeHUh?=
BB65-RCC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO0fWJKSzVyPUCuN|A1KG6P MX7TRW5ITVJ?
D-542MG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwM{K5JI5O NVjHfIlLW0GQR1XS
ONS-76 MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nl[mlEPTB;MD6zN{BvVQ>? MkS4V2FPT0WU
BB30-HNC NVnHTIRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvqeINKSzVyPUCuN|M2KG6P Mlv6V2FPT0WU
KS-1 MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\ROXJKSzVyPUCuN|Qhdk1? MljkV2FPT0WU
A388 NGPTcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwM{W2JI5O MmW3V2FPT0WU
ES8 M1fuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjM[|lKSzVyPUCuOEBvVQ>? MWTTRW5ITVJ?
MZ2-MEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[5TWM2OD1yLkSwO{BvVQ>? Moi4V2FPT0WU
HCC2998 NEPEWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj0TYV[UUN3ME2wMlQyOiCwTR?= NWTkToVRW0GQR1XS
D-247MG M3q1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwNEGzJI5O MVTTRW5ITVJ?
ACN NW\tdHhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDkUm5KSzVyPUCuOFE4KG6P NVXYflF5W0GQR1XS
LB2518-MEL M2\YbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjmTWM2OD1yLkSyOUBvVQ>? NGrXZ5ZUSU6JRWK=
ES1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwNEOgcm0> MUDTRW5ITVJ?
HCE-T NWm4SnpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17aeGlEPTB;MD60N|khdk1? MVTTRW5ITVJ?
OS-RC-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfBXZNKSzVyPUCuOFQhdk1? M1vP[nNCVkeHUh?=
MFH-ino Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPxTWM2OD1yLkS0N{BvVQ>? NEPXNY1USU6JRWK=
OCUB-M M{Hw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWyW3BwUUN3ME2wMlQ1PyCwTR?= M1HQXnNCVkeHUh?=
CP66-MEL MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XZVWlEPTB;MD60O|Mhdk1? MX\TRW5ITVJ?
LB771-HNC NIXOe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzPUpFKSzVyPUCuOFc1KG6P NVLOfFg2W0GQR1XS
DSH1 NGHRUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W5[2lEPTB;MD60PEBvVQ>? Mnv2V2FPT0WU
HUTU-80 NXH2b3VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS1TWM2OD1yLkWzN{BvVQ>? MnXoV2FPT0WU
CESS MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwNUO4JI5O NIPlOYdUSU6JRWK=
NCI-H747 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPmTWM2OD1yLkWzPUBvVQ>? NISyZ|FUSU6JRWK=
HT-144 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3KyUWlEPTB;MD61O|Yhdk1? MmrxV2FPT0WU
COLO-829 NF7FXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO2TWM2OD1yLk[xOEBvVQ>? MmnoV2FPT0WU
A4-Fuk NUjFb3VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PLRWlEPTB;MD62NlMhdk1? NX7qd49SW0GQR1XS
GI-ME-N MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoqzTWM2OD1yLk[zOEBvVQ>? NV6zTWxRW0GQR1XS
LB831-BLC MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe0WlZKSzVyPUCuOlQyKG6P NEjQXphUSU6JRWK=
HOP-62 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwNkS3JI5O NYTqeJdvW0GQR1XS
BB49-HNC NFrEZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\WNVRKSzVyPUCuOlUzKG6P Ml63V2FPT0WU
D-336MG M2jaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fUe2lEPTB;MD62OVchdk1? MnzPV2FPT0WU
TK10 NVPBUHcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T3bmlEPTB;MD62O|khdk1? M{XzfXNCVkeHUh?=
Ramos-2G6-4C10 NX;sbWd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInSXHBKSzVyPUCuOlk{KG6P NXzRcYtwW0GQR1XS
LB373-MEL-D M4\mfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3roZWlEPTB;MD63JI5O MVrTRW5ITVJ?
SF126 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33PN2lEPTB;MD63NFEhdk1? M3K2T3NCVkeHUh?=
UACC-257 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX0dXR5UUN3ME2wMlcyKG6P NGDIXGdUSU6JRWK=
KINGS-1 NUHDWGRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknRTWM2OD1yLkeyNkBvVQ>? NVe4ZYN1W0GQR1XS
LS-513 NIm0UpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[yTWM2OD1yLkezPUBvVQ>? M{i0fnNCVkeHUh?=
GI-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LFXmlEPTB;MD63OlQhdk1? M1PH[HNCVkeHUh?=
ES7 MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwN{[2JI5O NXzDVYdWW0GQR1XS
LB2241-RCC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnQVoVMUUN3ME2wMlgxPCCwTR?= NHmyOHNUSU6JRWK=
D-263MG NGDre|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GwR2lEPTB;MD64NFchdk1? NG\CN4lUSU6JRWK=
SW684 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvLSIpRUUN3ME2wMlgzOSCwTR?= MU\TRW5ITVJ?
ML-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;Td|VKSzVyPUCuPFIyKG6P NVeyPFF[W0GQR1XS
SK-LMS-1 NFjwNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwOEW0JI5O NWHBVpA{W0GQR1XS
TE-5 NX22ZVRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwOE[1JI5O NX;USZZUW0GQR1XS
QIMR-WIL M{fFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfTTWM2OD1yLki4PUBvVQ>? M13GUXNCVkeHUh?=
NCI-H1355 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PjS2lEPTB;MD64PVUhdk1? NYPzPW1PW0GQR1XS
SNB75 M4L5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX3TWM2OD1yLkmxNkBvVQ>? M1nlbnNCVkeHUh?=
RXF393 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPRSW1KSzVyPUCuPVE1KG6P NVTPPXBbW0GQR1XS
IST-MEL1 NWK0SZpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwOUG3JI5O MXLTRW5ITVJ?
SF268 M3LQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwOUKzJI5O M{LBOXNCVkeHUh?=
KALS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXITWM2OD1yLkmyOUBvVQ>? MUDTRW5ITVJ?
HC-1 MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPoN25KSzVyPUCuPVc2KG6P MlT6V2FPT0WU
SW872 NFzBRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLpXVF6UUN3ME2wMlk6PiCwTR?= M4HScHNCVkeHUh?=
PSN1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LQ[WlEPTB;MT6wNUBvVQ>? NGn0c2lUSU6JRWK=
TE-1 NHjhfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFwMEOgcm0> NHTs[mtUSU6JRWK=
TE-10 M3[2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwMEOgcm0> NILSXFhUSU6JRWK=
RKO NVGwfINIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT0TWM2OD1zLkC2JI5O MX\TRW5ITVJ?
LC-2-ad NFLjTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwMEigcm0> MUDTRW5ITVJ?
SK-MM-2 NXj1TW9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHZ[lJZUUN3ME2xMlA6KG6P MluxV2FPT0WU
VA-ES-BJ NHfUVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfTXmgyUUN3ME2xMlA6KG6P Ml;pV2FPT0WU
MZ7-mel MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPFNGdbUUN3ME2xMlA6KG6P M1Xr[HNCVkeHUh?=
D-392MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwMTDuUS=> M3vzSXNCVkeHUh?=
CCRF-CEM NES5[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj3SVZKSzVyPUGuNVMhdk1? MUXTRW5ITVJ?
EM-2 NIC4VJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVry[3VQUUN3ME2xMlE3KG6P M{PhW3NCVkeHUh?=
HAL-01 NWHPVWVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFKzcIFKSzVyPUGuNVghdk1? NILrTppUSU6JRWK=
TE-8 Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPablNYUUN3ME2xMlE6KG6P MX;TRW5ITVJ?
NCI-H1882 NVHlfZlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2njZmlEPTB;MT6yJI5O MU\TRW5ITVJ?
Daudi NILwUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDhWpBKSzVyPUGuNlIhdk1? MlTpV2FPT0WU
BL-41 MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH6Z|B6UUN3ME2xMlI2KG6P Mn\vV2FPT0WU
SR NUjITnBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTZTWM2OD1zLkK1JI5O NFroUHJUSU6JRWK=
KM12 NIXUUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTXfodoUUN3ME2xMlI4KG6P NV7qfIhzW0GQR1XS
K5 Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL4NpJQUUN3ME2xMlI5KG6P NE\2bnlUSU6JRWK=
A3-KAW MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPsNnBKSzVyPUGuNlghdk1? MYfTRW5ITVJ?
CMK NHzQZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPQU2hKSzVyPUGuNlkhdk1? MlHEV2FPT0WU
Calu-6 M4jOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFwMkmgcm0> M3HhNHNCVkeHUh?=
IST-SL2 Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXCOWZKSzVyPUGuN|Ehdk1? NXHJRY9IW0GQR1XS
OPM-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2KzVWlEPTB;MT6zN{BvVQ>? MUnTRW5ITVJ?
DU-4475 NUnhemtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLyRlJKSzVyPUGuN|Yhdk1? NVfWUJlRW0GQR1XS
ECC12 NXHnVIpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFwM{egcm0> M3vCdnNCVkeHUh?=
L-540 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwM{egcm0> MUPTRW5ITVJ?
CAS-1 MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfGWnBKSzVyPUGuN|chdk1? NW\DNHZiW0GQR1XS
PF-382 NFrsTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O5XGlEPTB;MT60O{BvVQ>? NH\KPJpUSU6JRWK=
LS-411N M1rX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfxTWM2OD1zLkWzJI5O MYrTRW5ITVJ?
NCI-H69 M1fKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPZTWM2OD1zLkW0JI5O MWDTRW5ITVJ?
NB12 M{X2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwNU[gcm0> MlntV2FPT0WU
HEL NIPyNGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfCVXMxUUN3ME2xMlYyKG6P NUniOGExW0GQR1XS
GCIY NV;Qe2F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFwNkKgcm0> MljtV2FPT0WU
EHEB Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHTZlVXUUN3ME2xMlY4KG6P MojsV2FPT0WU
TGBC1TKB M{i2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwN{Ggcm0> NHPPNWhUSU6JRWK=
KURAMOCHI M4C1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPnTWM2OD1zLkeyJI5O MoTIV2FPT0WU
U-266 NFO1OGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nSTmlEPTB;MT63OkBvVQ>? NUPRTXNoW0GQR1XS
LC4-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVf2Tos6UUN3ME2xMlc6KG6P MmSyV2FPT0WU
NCI-H2126 M4rPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e0[WlEPTB;MT64JI5O NFzRPYxUSU6JRWK=
NCI-H1092 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HoUGlEPTB;MT64JI5O NInJWZdUSU6JRWK=
GB-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mwNmlEPTB;MT64NUBvVQ>? NEPHNHRUSU6JRWK=
MV-4-11 M37pcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTRTWM2OD1zLkiyJI5O NYP0cGlDW0GQR1XS
Becker MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLYTWM2OD1zLkizJI5O MVzTRW5ITVJ?
MPP-89 NYexV45JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwOEmgcm0> MljGV2FPT0WU
BE-13 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwOUOgcm0> NIPYXHdUSU6JRWK=
697 M1zxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7oTFlHUUN3ME2xMlk6KG6P MmfiV2FPT0WU
NKM-1 Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvFTWM2OD1{IH7N MXHTRW5ITVJ?
NB13 NXHhVVhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXKXIFbUUN3ME2yJI5O MYHTRW5ITVJ?
LS-123 NUXCZmx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTYTWM2OD1{LkCyJI5O M4m2eHNCVkeHUh?=
NB17 M{LFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJwMESgcm0> MUjTRW5ITVJ?
LAN-6 NH\0bpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJwMEWgcm0> MnfrV2FPT0WU
EW-24 NUDaRVdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojGTWM2OD1{LkC4JI5O MUHTRW5ITVJ?
NOS-1 NYjURoMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e1N2lEPTB;Mj6xNUBvVQ>? NFywUZZUSU6JRWK=
BL-70 M3HnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHNTWM2OD1{LkGyJI5O NVzLfndJW0GQR1XS
GT3TKB NYjKNFM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7kTWM2OD1{LkGyJI5O NIHP[Y5USU6JRWK=
HH M3fmS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTCOYFKSzVyPUKuNVMhdk1? MmrsV2FPT0WU
KE-37 M1XheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CxTmlEPTB;Mj6xN{BvVQ>? NILnXYRUSU6JRWK=
MOLT-4 MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDDV4VQUUN3ME2yMlE{KG6P MX\TRW5ITVJ?
EKVX M3e3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTTTWM2OD1{LkG0JI5O M{PoPXNCVkeHUh?=
KGN M4LBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJwMUWgcm0> NYr0clJoW0GQR1XS
ES4 NHzFdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJwMU[gcm0> NWWzcFdKW0GQR1XS
SJSA-1 M4PkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnnVJhYUUN3ME2yMlIyKG6P NYTKPGxGW0GQR1XS
KMOE-2 MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf6dJNGUUN3ME2yMlI{KG6P MmPjV2FPT0WU
NB5 NHi5cHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LhUGlEPTB;Mj6yO{BvVQ>? MUHTRW5ITVJ?
BC-1 MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJwM{Ggcm0> NGrDS|hUSU6JRWK=
NB10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q3eGlEPTB;Mj6zNkBvVQ>? NEnoRmpUSU6JRWK=
RPMI-8226 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjRXmZ4UUN3ME2yMlM2KG6P NFj0fZpUSU6JRWK=
SCC-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfnN4N2UUN3ME2yMlM4KG6P NILweJVUSU6JRWK=
ARH-77 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHwTWM2OD1{LkO4JI5O M2LETnNCVkeHUh?=
NCI-H748 M2rlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX0SpJKSzVyPUKuN|khdk1? MVrTRW5ITVJ?
KU812 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\RdWlCUUN3ME2yMlQzKG6P MmPyV2FPT0WU
NCI-H64 NYnrWJpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fJWmlEPTB;Mj60OEBvVQ>? MlrsV2FPT0WU
NB69 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;xeGlEPTB;Mj60OkBvVQ>? Mom4V2FPT0WU
KNS-81-FD MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHsfoFKSzVyPUKuOFghdk1? MonaV2FPT0WU
LB1047-RCC M1LZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHWxO5dKSzVyPUKuOVchdk1? MVjTRW5ITVJ?
EB-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\IdWlEPTB;Mj62OkBvVQ>? MWPTRW5ITVJ?
Mo-T MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPlTWM2OD1{Lke0JI5O NYT1dG02W0GQR1XS
EW-16 NIDablFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnuXYVDUUN3ME2yMlc2KG6P MlSxV2FPT0WU
CTV-1 NHnkfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfkOYlKSzVyPUKuPEBvVQ>? M2e2eHNCVkeHUh?=
ETK-1 NYnVclZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm5NIhvUUN3ME2yMlg1KG6P NXTGOFNPW0GQR1XS
C2BBe1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrI[Y9GUUN3ME2yMlg6KG6P MYPTRW5ITVJ?
MOLT-16 NVPsPWNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTiVZd[UUN3ME2yMlg6KG6P MlXwV2FPT0WU
SW954 NVv6PWhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX4fWZKSzVyPUKuPUBvVQ>? NGDuT|BUSU6JRWK=
HT NIXkRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHDUJJKSzVyPUOuNFIhdk1? MmnxV2FPT0WU
KARPAS-299 NEPVc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNwME[gcm0> MWLTRW5ITVJ?
MONO-MAC-6 M1;DRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3tdnlKSzVyPUOuNUBvVQ>? NIrGSVVUSU6JRWK=
CGTH-W-1 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwMTDuUS=> NH6yfoRUSU6JRWK=
SK-PN-DW MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnyzTWM2OD1|LkG0JI5O MXfTRW5ITVJ?
CW-2 MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILTUGtKSzVyPUOuNlEhdk1? M3HIPHNCVkeHUh?=
SK-N-DZ NHLRcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP5UFZTUUN3ME2zMlI3KG6P MmDZV2FPT0WU
NEC8 NULYeINTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLsTWM2OD1|LkO1JI5O NHfUdpZUSU6JRWK=
LB996-RCC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[5TWM2OD1|LkSgcm0> NE\xWYFUSU6JRWK=
DB M4\jcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\aTWM2OD1|LkSxJI5O NIjiOJlUSU6JRWK=
TE-15 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPlZ49KSzVyPUOuOFMhdk1? MmWwV2FPT0WU
COR-L88 NFzTU|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonRTWM2OD1|LkS3JI5O MljKV2FPT0WU
LAMA-84 NYSyUVlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPHR|NKUUN3ME2zMlQ6KG6P NF7RfGdUSU6JRWK=
MEG-01 MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S3SGlEPTB;Mz60PUBvVQ>? NVTpNnlMW0GQR1XS
LOXIMVI NYT6eHZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfaempKSzVyPUOuOUBvVQ>? MV3TRW5ITVJ?
RPMI-8402 NXq4e3A5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvjRVdKSzVyPUOuOUBvVQ>? NWfuXVVPW0GQR1XS
KARPAS-45 NIHZeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqwTWM2OD1|LkW0JI5O NG\DWW5USU6JRWK=
HCC1187 MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Cy[mlEPTB;Mz61OEBvVQ>? MVHTRW5ITVJ?
MZ1-PC NGfhWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS5TWM2OD1|LkW0JI5O MmS5V2FPT0WU
no-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nyRmlEPTB;Mz61OUBvVQ>? MnHCV2FPT0WU
EVSA-T NHLRXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLRSVlNUUN3ME2zMlYhdk1? M3XNR3NCVkeHUh?=
DJM-1 NYD1T4l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3qd3RWUUN3ME2zMlY{KG6P Ml63V2FPT0WU
COLO-684 NELONpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLCT5pKSzVyPUOuOlYhdk1? MonJV2FPT0WU
NMC-G1 M3WydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X0[2lEPTB;Mz62PEBvVQ>? M{m5dnNCVkeHUh?=
LC-1F MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\5UGlEPTB;Mz63OEBvVQ>? MXfTRW5ITVJ?
RL95-2 NVrYbWlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVruWllHUUN3ME2zMlc6KG6P M{jaNHNCVkeHUh?=
COLO-320-HSR Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTNwOUKgcm0> M{LqUHNCVkeHUh?=
RCC10RGB MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTNwOUOgcm0> MnHIV2FPT0WU
HD-MY-Z Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTNwOUOgcm0> NIO4W|VUSU6JRWK=
NCI-H2141 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLW[lVUUUN3ME20MlA2KG6P M{nuU3NCVkeHUh?=
K-562 NYLMcJMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\uS5dKSzVyPUSuNVIhdk1? Mor0V2FPT0WU
NCI-H1648 NFfyXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXwdlZrUUN3ME20MlE{KG6P M2PvO3NCVkeHUh?=
OMC-1 NIfRNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTzfJNKSzVyPUSuNVghdk1? NHvNUllUSU6JRWK=
LB647-SCLC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DaS2lEPTB;ND6yNkBvVQ>? MmS2V2FPT0WU
TE-12 M3zzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Szd2lEPTB;ND6yOUBvVQ>? NIfCO2RUSU6JRWK=
NOMO-1 M{\wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTkTWM2OD12LkOzJI5O NWraXXJQW0GQR1XS
Raji MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTRwNE[gcm0> M2Xl[nNCVkeHUh?=
NALM-6 NWnsR|lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33VOmlEPTB;ND60PUBvVQ>? NV7VUII6W0GQR1XS
HL-60 MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTRwNkegcm0> NXrI[JltW0GQR1XS
IST-SL1 M37CNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnuTWM2OD12Lk[4JI5O NHvoeWZUSU6JRWK=
MHH-PREB-1 NEGyS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHDXWZCUUN3ME20Mlg3KG6P M4PsNXNCVkeHUh?=
MHH-NB-11 NVXtbm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HZW2lEPTB;ND65NUBvVQ>? MkDyV2FPT0WU
JiyoyeP-2003 NHXUZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTrVY9KSzVyPUWgcm0> NHrQdG1USU6JRWK=
SBC-1 M1O5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDwTWM2OD13LkCxJI5O MUjTRW5ITVJ?
CHP-126 NFvuPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonXTWM2OD13LkC2JI5O M4HKbXNCVkeHUh?=
LU-139 MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf6OYtoUUN3ME21MlE{KG6P MXTTRW5ITVJ?
NCI-SNU-5 NU\qdYJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qyOmlEPTB;NT6xO{BvVQ>? M2myO3NCVkeHUh?=
SW962 NUTFflY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C4V2lEPTB;NT6yNUBvVQ>? M1TSWnNCVkeHUh?=
EW-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjwTWM2OD13LkOxJI5O MWLTRW5ITVJ?
NCI-H1417 M3TVR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTVwNUGgcm0> MYnTRW5ITVJ?
LU-65 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\Hd|A1UUN3ME21Mlg1KG6P M1W2d3NCVkeHUh?=
D-502MG NEW5[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33oRmlEPTB;Nj6zO{BvVQ>? M1rrSnNCVkeHUh?=
BC-3 NH\JTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37ibWlEPTB;Nj62NUBvVQ>? MYPTRW5ITVJ?
GDM-1 NXPYOm1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\WcW5KSzVyPU[uO|chdk1? NWHIc4xOW0GQR1XS
NCI-H2196 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jm[mlEPTB;Nj64JI5O M3jUVXNCVkeHUh?=
NB1 M1\Db2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{OwSWlEPTB;Nj64PEBvVQ>? NFOzcmlUSU6JRWK=
NCI-H345 M3:wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW2e3BkUUN3ME23MlIhdk1? NHnVS5ZUSU6JRWK=
SU-DHL-1 Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W0NmlEPTB;Nz6yOEBvVQ>? M36zUXNCVkeHUh?=
JVM-2 Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrSWGJKSzVyPUeuNlghdk1? Ml\vV2FPT0WU
LU-134-A NXzyTmxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTdwM{mgcm0> NHHr[nRUSU6JRWK=
NCI-H1694 NHeyfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LFfmlEPTB;Nz61PEBvVQ>? Mn;UV2FPT0WU
NCI-SNU-16 NE\VZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fTTGlEPTB;Nz62OUBvVQ>? MkDqV2FPT0WU
L-363 NHHQNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXHV5JKSzVyPUeuO{BvVQ>? M2TXcHNCVkeHUh?=
KG-1 M1jO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHMZWxKSzVyPUeuPVQhdk1? MlP6V2FPT0WU
MN-60 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\seJBrUUN3ME24MlE1KG6P NGPkNHFUSU6JRWK=
NB6 NVfyV3E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTTV2lXUUN3ME24MlQ5KG6P M1jpS3NCVkeHUh?=
MLMA M16xUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRThwOEWgcm0> MoW5V2FPT0WU
ATN-1 NF3ZcFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT0OmE{UUN3ME24Mlg6KG6P NEO4WnlUSU6JRWK=
SK-NEP-1 NHfWXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7yW4JKSzVyPUmuNFEhdk1? Mm\XV2FPT0WU
DMS-114 MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGKxWXRKSzVyPUmuOlIhdk1? NHPGPFZUSU6JRWK=
CTB-1 NWrYSIx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknpTWM2OD17Lk[3JI5O NYHLR4F2W0GQR1XS
NCI-H2081 M2jlcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTFyLkC5JI5O NFHkcllUSU6JRWK=
ES5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFyLkO4JI5O NEPJ[mRUSU6JRWK=
HCC1599 NVzSXWxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXVTWM2OD1zMT65NUBvVQ>? NXO3R5ptW0GQR1XS
NCI-H23 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r0VmlEPTB;MUKuNVIhdk1? NWX5fYxZW0GQR1XS
NCI-H1581 M2nQbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF{LkK4JI5O MXfTRW5ITVJ?
JVM-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3LTWM2OD1zMj65PUBvVQ>? NFTzeGpUSU6JRWK=
NCI-SNU-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n6cmlEPTB;MUOuNVkhdk1? MX\TRW5ITVJ?
NB7 NW[3XHFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjIWZNuUUN3ME2xOU46OiCwTR?= NI\ybphUSU6JRWK=
JAR NXjOVFU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPpepB[UUN3ME2xOk4yOyCwTR?= NFrV[ZZUSU6JRWK=
TGW NYT3WXQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTF4LkS4JI5O NIS2bpRUSU6JRWK=
U-87-MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlruTWM2OD1zNj63OkBvVQ>? M37FNXNCVkeHUh?=
NCI-H1436 NXWwXWZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M121NGlEPTB;MUeuNFEhdk1? NEG2PHVUSU6JRWK=
GOTO MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF35[4dKSzVyPUG3MlA3KG6P NGHxRllUSU6JRWK=
COLO-800 NFHlfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M360NGlEPTB;MUeuOlQhdk1? M3HxSHNCVkeHUh?=
MFM-223 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvBZ|lbUUN3ME2xO{46OSCwTR?= MVfTRW5ITVJ?
EW-18 M1vMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXKTnl1UUN3ME2xO{46PiCwTR?= NXqzU5dHW0GQR1XS
NB14 NH;DflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q1RWlEPTB;MUeuPVghdk1? NGrIU2hUSU6JRWK=
EB2 NF3mbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;vPFdKSzVyPUG4MlA5KG6P NXvW[YhiW0GQR1XS
EoL-1- NX\1TFk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHxRZpXUUN3ME2xPE4{OSCwTR?= NEHqXpJUSU6JRWK=
NCCIT NXz1VG9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfZUlhKSzVyPUG4MlM3KG6P Ml:xV2FPT0WU
DG-75 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnntTWM2OD1zOD62NUBvVQ>? MVXTRW5ITVJ?
HCC2218 NULncpJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\pOmlEPTB;MUmuOUBvVQ>? MkjWV2FPT0WU
TE-6 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfRVnV1UUN3ME2yNE4xQCCwTR?= NVHBWohtW0GQR1XS
SF539 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fUVWlEPTB;MkCuOlchdk1? MXzTRW5ITVJ?
NCI-H446 M{nCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;Wd2dCUUN3ME2yNU4yQCCwTR?= MX;TRW5ITVJ?
IST-MES1 M2e3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFraSVJKSzVyPUKyMlc4KG6P NHS2eolUSU6JRWK=
NCI-H82 NX31W3JxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TGb2lEPTB;MkOuNFIhdk1? M4XRTnNCVkeHUh?=
HCC2157 NGTY[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrnWnd5UUN3ME2yN{4yOyCwTR?= MV\TRW5ITVJ?
EW-12 NX\wfGxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJ|LkG3JI5O NH;yZ3NUSU6JRWK=
SIMA MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ|LkO4JI5O NV[4OII6W0GQR1XS
DOHH-2 NG\zbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L0[2lEPTB;MkOuOFUhdk1? MmjZV2FPT0WU
IM-9 MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTOTWM2OD1{Mz61OEBvVQ>? NEXERnBUSU6JRWK=
EC-GI-10 NIraPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPCWGRpUUN3ME2yOE4zOyCwTR?= NI\C[2FUSU6JRWK=
HDLM-2 NHLjWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH4b5ZIUUN3ME2yOE42PCCwTR?= NFvlZ5JUSU6JRWK=
LS-1034 MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXmTWM2OD1{NT63OUBvVQ>? Mm\EV2FPT0WU
REH NWHXSol5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uzbWlEPTB;Mk[uOFEhdk1? MXnTRW5ITVJ?
LU-165 MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnETWM2OD1{Nj63NkBvVQ>? NUXzZmwxW0GQR1XS
NH-12 NUH3[WJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LZU2lEPTB;MkeuOlchdk1? NHnUR45USU6JRWK=
WSU-NHL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHvNpVKSzVyPUK4MlM6KG6P NUDpSIRkW0GQR1XS
ECC4 NH;Z[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV24fJVMUUN3ME2yPE44QSCwTR?= NILSUnhUSU6JRWK=
OCI-AML2 NVuwdpY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITDdVFKSzVyPUK5MlY6KG6P MmDpV2FPT0WU
EW-3 NIHzRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfnTWM2OD1|MD61PUBvVQ>? M1PvWHNCVkeHUh?=
NCI-H526 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6yXmVDUUN3ME2zNk42PCCwTR?= NWHoTVU{W0GQR1XS
NCI-H719 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTN2LkOxJI5O M1f2[HNCVkeHUh?=
KARPAS-422 M4\uT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny0TWM2OD1|NT6wOEBvVQ>? NH\3fVVUSU6JRWK=
SK-MEL-1 M1W2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLHTWM2OD1|NT6xO{BvVQ>? NVTvWWRiW0GQR1XS
ES3 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnhTWM2OD1|NT6xPUBvVQ>? NIq5bYpUSU6JRWK=
UACC-812 NHvyeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPHTWM2OD1|NT60OEBvVQ>? M{\yNHNCVkeHUh?=
C8166 Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LTNmlEPTB;M{WuO{BvVQ>? MnSzV2FPT0WU
MDA-MB-134-VI M4HOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LVO2lEPTB;M{WuPFchdk1? MW\TRW5ITVJ?
D-283MED MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi0RVBNUUN3ME2zO{44QSCwTR?= NY[yfG5vW0GQR1XS
SHP-77 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTN6LkCzJI5O MYLTRW5ITVJ?
NCI-H2227 Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPrbIpKSzVyPUSwMlQ6KG6P NFLnSlJUSU6JRWK=
SKM-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\ubohKSzVyPUSyMlY{KG6P M1jVbHNCVkeHUh?=
L-428 NEHvTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHziUIpKSzVyPUSzMlg3KG6P NXrwSJZWW0GQR1XS
RPMI-6666 M4HRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPRbI9KSzVyPUS1Mlg6KG6P M1nWUnNCVkeHUh?=
NCI-H716 M1H6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTuTJMxUUN3ME20PE45OSCwTR?= MUDTRW5ITVJ?
DMS-79 NXz1T|dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzVblR6UUN3ME21NE44OSCwTR?= MVTTRW5ITVJ?
RS4-11 NHn3bHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\FbmlEPTB;NUCuPFghdk1? MonZV2FPT0WU
NCI-H720 NXjzPWJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37B[mlEPTB;NUGuNVEhdk1? M1i5bXNCVkeHUh?=
MC-CAR MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnoXVB2UUN3ME21NU42OiCwTR?= MnTGV2FPT0WU
TALL-1 MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHaTWM2OD13Mz65NUBvVQ>? MULTRW5ITVJ?
NCI-N87 Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXJfJBKSzVyPUW0MlE5KG6P NUHTVJlJW0GQR1XS
P30-OHK NGm3TpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTV2Lk[xJI5O MnzPV2FPT0WU
LP-1 NXLORpQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HDc2lEPTB;NkGuNlghdk1? M1fsXnNCVkeHUh?=
YT NVPUV2E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\kc5hKSzVyPU[xMlghdk1? NGfOe2FUSU6JRWK=
MRK-nu-1 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUGxWlNiUUN3ME22NU45OiCwTR?= NH\1R5NUSU6JRWK=
BT-474 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTZ3IH7N NUPZSVFZW0GQR1XS
NCI-H322M M1e4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4iyVGlEPTB;Nk[uNVEhdk1? NInPUHlUSU6JRWK=
NCI-H128 MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnNTWM2OD15ND63O{BvVQ>? MVLTRW5ITVJ?
KMS-12-PE NHzsZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P6OGlEPTB;N{[uNlQhdk1? Mnz2V2FPT0WU
KP-N-YS NFLBToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTd4Lke0JI5O NULRbWQ2W0GQR1XS
ALL-PO NFzZOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXITWM2OD15Nz62OkBvVQ>? NIrIUJhUSU6JRWK=
EW-13 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTwTWM2OD15Nz63OkBvVQ>? MVHTRW5ITVJ?
EW-11 M1u1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTd6LkWyJI5O M3fSNnNCVkeHUh?=
SK-N-FI M1S0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\SWHhKSzVyPUiwMlIhdk1? NXrMZ|JMW0GQR1XS
CAL-148 M1ziU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPObHFKSzVyPUixMlg1KG6P MoHOV2FPT0WU
RL MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTh4LkC5JI5O MX7TRW5ITVJ?
AM-38 MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnftTWM2OD16OD6wPEBvVQ>? NG\0Rm1USU6JRWK=
RH-1 M2fuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTl7Lki1JI5O M3npUHNCVkeHUh?=
NCI-H1770 NUTvRpQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvoTWM2OD1zMEKuOFkhdk1? Mli2V2FPT0WU
SIG-M5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nTRWlEPTB;MUC1MlA3KG6P Ml3oV2FPT0WU
GR-ST NHyxVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP0dWZKSzVyPUGxN{4{PCCwTR?= M1nid3NCVkeHUh?=
ST486 M4PMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrjVG9KSzVyPUGxOE4xPiCwTR?= NYOzd2U2W0GQR1XS
NCI-H1650 NH3ETlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknFTWM2OD1zMUWuNlkhdk1? MonaV2FPT0WU
MHH-CALL-2 NHHBfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rZO2lEPTB;MUG1Mlchdk1? M{HMNXNCVkeHUh?=
BV-173 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDRTWM2OD1zMkKuO|Ehdk1? NY\VfIlWW0GQR1XS
MC116 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7v[YpUUUN3ME2xOFgvQDVibl2= NV;ZWoxLW0GQR1XS
NCI-H524 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDlTWM2OD1zNUmuNUBvVQ>? NHroRoFUSU6JRWK=
SCLC-21H Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF3OT60NUBvVQ>? M{jRTnNCVkeHUh?=
NCI-H1304 M2XGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\uN20zUUN3ME2xOlkvOjFibl2= M2Xle3NCVkeHUh?=
NCI-H510A NGnPdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHvSWhKSzVyPUG4OU4{PyCwTR?= MXTTRW5ITVJ?
NCI-H209 M33Ucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[zfphpUUN3ME2xPVYvPTJibl2= NFn0bW1USU6JRWK=
KM-H2 NE\2T2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnNWo5CUUN3ME2xPVcvODVibl2= MkjkV2FPT0WU
NCI-H1395 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLNVXNKSzVyPUKxNE4yOyCwTR?= NWnnSJg1W0GQR1XS
NCI-H1155 NVnEeo45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrsRXRKSzVyPUKzNE4{OiCwTR?= MVrTRW5ITVJ?
COR-L279 NHnIZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ3Mj6xO{BvVQ>? NFn6fJJUSU6JRWK=
NCI-H1299 M1T6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJ4MT63NUBvVQ>? MkfWV2FPT0WU
EW-22 NG\OXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL4[4EyUUN3ME2yOlMvPzVibl2= MoXvV2FPT0WU
SK-MEL-2 MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TENGlEPTB;MkixMlkhdk1? NH;LS4pUSU6JRWK=
KASUMI-1 NYHvTmp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q3fWlEPTB;MkizMlA2KG6P NWfzZVNFW0GQR1XS
NCI-H187 NFvH[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nyTmlEPTB;Mki3MlA5KG6P NHrKbohUSU6JRWK=
NCI-H2171 NFfCUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJ6OD65NkBvVQ>? NH[zOFFUSU6JRWK=
LNCaP-Clone-FGC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\iTWM2OD1{OUWuNlYhdk1? NUnvemQ2W0GQR1XS
NCI-H1522 NH7mdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Pv[2lEPTB;M{C3MlA2KG6P NELmVmxUSU6JRWK=
SCH NEPWcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3lR|lKSzVyPUOyNk4zOiCwTR?= MXLTRW5ITVJ?
THP-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTN{Mj62JI5O NWfv[pRvW0GQR1XS
SNU-C1 M1u5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHtRoRoUUN3ME2zOlIvODlibl2= NWLHWYtYW0GQR1XS
CA46 MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPaTWM2OD1|N{OuOlMhdk1? M4nndHNCVkeHUh?=
NCI-H1963 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XlfGlEPTB;M{i2MlE6KG6P MXnTRW5ITVJ?
DEL NUX5d4ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTN7MT6yO{BvVQ>? MXzTRW5ITVJ?
TUR MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPueXRZUUN3ME2zPVYvPjFibl2= NXLubIhzW0GQR1XS
NCI-H226 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTRyMz6yN{BvVQ>? NXHONW9FW0GQR1XS
COLO-668 NULRWFRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWqyPXVHUUN3ME20NFMvPTdibl2= NIH1[GtUSU6JRWK=
CPC-N MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHtSoVKSzVyPUSwN{44PyCwTR?= MV;TRW5ITVJ?
NCI-H889 MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTzTWM2OD12NkGuPVIhdk1? MVnTRW5ITVJ?
J-RT3-T3-5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;vTWM2OD13M{KuOVchdk1? NXqzdoFRW0GQR1XS
MSTO-211H NFTZXHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LsbWlEPTB;NUe0MlI3KG6P Ml\yV2FPT0WU
SCC-15 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTZ4Nz60O{BvVQ>? NVrKeWwzW0GQR1XS
SUP-T1 M2X3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTZ6Nj6wOEBvVQ>? Mkn2V2FPT0WU
DMS-153 NEHNeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLi[WFKSzVyPUe0Ok45OyCwTR?= MXvTRW5ITVJ?
MS-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\mS2lEPTB;N{W5MlQzKG6P M4PTbnNCVkeHUh?=
TC-YIK MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL5PZNKSzVyPUe4NU4xOSCwTR?= NUjWUIhKW0GQR1XS
RPMI-8866 NVrJUo9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vCTWlEPTB;MUCwOk4zQCEQvF2= NGDFbYFUSU6JRWK=
KY821 M1zZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXJTWM2OD1zMEO2MlA1KM7:TR?= MoX2V2FPT0WU
P31-FUJ MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPpS5VZUUN3ME2xNVEzNjd3IN88US=> MWLTRW5ITVJ?
COLO-824 M1;uSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULzbW85UUN3ME2xNlYyNjd6IN88US=> MXHTRW5ITVJ?
U-698-M NHzvfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HrSmlEPTB;MkK2Nk4yPSEQvF2= Mn;WV2FPT0WU
TE-441-T NYTJcGh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTQWnpKSzVyPUK1NlEvPyEQvF2= MYLTRW5ITVJ?
IMR-5 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnMPIlGUUN3ME2zOFA6NjZ{IN88US=> Mk\RV2FPT0WU
NCI-H1838 Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\TOVNKSzVyPUSxPFYvOzJizszN NUHF[4o1W0GQR1XS

... Click to View More Cell Line Experimental Data
In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]
+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]
+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]
+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4
CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03136146 Recruiting Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma M.D. Anderson Cancer Center August 9 2017 Phase 2
NCT02195479 Active not recruiting Multiple Myeloma Janssen Research & Development LLC December 9 2014 Phase 3
NCT01449344 Active not recruiting Mantle Cell Lymphoma Prof. Dr. M. Dreyling (co-chairman)|Klinikum der Universitaet Muenchen Grosshadern|ClinAssess GmbH|GELARC Service de Pharmacovigilance Pierre Benite|European Mantle Cell Lymphoma Network May 9 2009 Phase 3
NCT00703664 Completed Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma National Cancer Institute (NCI) July 9 2008 Phase 2
NCT01965977 Recruiting Diffuse Large B Cell Lymphoma Samsung Medical Center|Janssen LP April 8 2015 Phase 2
NCT01818752 Completed Multiple Myeloma Amgen July 8 2013 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

selleck catalog

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

  • Classic Proteasome Inhibitor

    ONX-0914 (PR-957) : Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Related Proteasome Products

  • VR23 New

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin New

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat (BB-2516) New

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • Ixazomib Citrate (MLN9708)

    Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID